US 12,275,732 B2
Cyclic compounds as receptor modulating therapeutics and methods and uses thereof
Lorna Mitchell, Thebarton (AU); Hamish Toop, Thebarton (AU); Belinda Huff, Thebarton (AU); Justin Ripper, Thebarton (AU); Rajinder Singh, Thebarton (AU); Christophe Morice, Widensolen (FR); Jean-Marie Contreras, Westhouse (FR); Patrick Bazzini, Strasbourg (FR); Laurent Schaeffer, Fortschwihr (FR); and Mathieu Michaut, Illkirch (FR)
Assigned to Bionomics Limited, Eastwood (AU)
Appl. No. 17/285,064
Filed by Bionomics Limited, Eastwood (AU)
PCT Filed Oct. 18, 2019, PCT No. PCT/AU2019/051137
§ 371(c)(1), (2) Date Apr. 13, 2021,
PCT Pub. No. WO2020/077414, PCT Pub. Date Apr. 23, 2020.
Claims priority of application No. 2018903949 (AU), filed on Oct. 18, 2018.
Prior Publication US 2021/0355124 A1, Nov. 18, 2021
Int. Cl. C07D 471/04 (2006.01); C07D 519/00 (2006.01)
CPC C07D 471/04 (2013.01) [C07D 519/00 (2013.01)] 10 Claims
 
1. A compound of formula (I):

OG Complex Work Unit Chemistry
wherein:
R1is

OG Complex Work Unit Chemistry
where g and r are independently 1, 2 or 3;

OG Complex Work Unit Chemistry
where q and s are independently 1, 2 or 3;
3-oxa-7-azabicyclo [3.3.1] nonane-7-yl group;
3-oxa-8-azabicyclo [3.2.1] octane-8-yl group;
3-oxa-3-azabicyclo [3.2.1] octane-8-yl group; or
3-oxa-9-azabicyclo [3.3.1] nonane-9-yl group;
R2 is a C1-C3 alkyl; and
X1, X2, X3 are independently CH or N wherein at least one of X1, X2 or X3 is N,
or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer or tautomer thereof.